# Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany – FDA Inspection, Feb 17, 2023

Source: https://www.keypedia.com/records/fda_inspections/halo-pharmaceutical-inc-dba-cambrex-whippany/977b66ca-6f39-4a4d-b230-c50aeda40300
Source feed: FDA_Inspections

> FDA inspection 1197680 of Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany, February 17, 2023. Classification: No Action Indicated (NAI). 1 citation under 21 CFR part 211. Form 483 issued. 12 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1197680
- Company Name: Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany
- Inspection Date: 2023-02-17
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 1

## Related Documents

- [FDA Inspection 1297650 - 2025-12-08](https://www.keypedia.com/records/fda_inspections/halo-pharmaceutical-inc-dba-cambrex-whippany/ff5fde2e-4f0e-44b5-9fd6-ece34ceb3753)
- FDA Inspection 1116333 - 2019-12-20
- [FDA Inspection 1055544 - 2018-05-30](https://www.keypedia.com/records/fda_inspections/halo-pharmaceutical-inc-dba-cambrex-whippany/00b592a9-1ab3-4d40-bb44-5de67256700c)
- FDA Inspection 1027562 - 2017-08-24
- [FDA Inspection 1008344 - 2017-03-20](https://www.keypedia.com/records/fda_inspections/halo-pharmaceutical-inc-dba-cambrex-whippany/9a730984-8411-4cbd-89ee-7407053ace5a)

## Related Officers

- [Issuing Officer](https://www.keypedia.com/people/maotang-zhou/72134574-d2ac-4401-9058-d99c3885cc47)
- [Investigator](https://www.keypedia.com/people/robin-p-mathew/35f4a085-58b8-4208-a648-ef2d533e1ece)

Company: https://www.keypedia.com/companies/halo-pharmaceutical-inc-dba-cambrex-whippany/1464443d-ae5a-4d06-959c-d1ccb1b213a2

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
